Introduction
The use of the immunoglobulin palivizumab for the prophylaxis of the Respiratory Syncytial Virus (RSV) in children under 2 years old is not a worldwide consensus.
In some countries, such as Brazil, public health policies (1) recommend its use for high-risk children, while in others cases it is necessary to establish more restrictive criteria for this measure, due to its low impact on the reduction of hospitalization and of RSV mortality in relation to costs generated (2) .
Newborns with previous health problems, such as prematurity, heart disease, immunosuppression and Chronic Lung Diseases (CLD), are at higher risk of developing severe illness and requiring hospitalization due to the RSV (3) (4) . In these cases, it is estimated that, at one year old, 69% of the children will have already shown some symptoms of infection and, at 2 years old, almost all of them will have presented at least one infectious condition and half of them will have had at least two infections (5) . Therefore, children with high risk of developing RSV illness should be identified to use this immunoglobulin, since current scientific evidence shows that this group gets the most significant advantages, such as a decrease in the frequency of hospitalization and in morbidity and mortality rates (6) .
Based on data from the Sentinel Surveillance
Information System on influenza, the seasonal peak of the virus in the Southeast, Central-West and Northeast regions, was identified as between March and July; in the North Region, this period occurs from February to June; and in the South Region, it occurs from April to August, earlier periods than the ones found in previous assessments (7) .
The first country to approve the use of the immunoglobulin palivizumab in children at high risk of developing RSV infection was the United States of America (USA) in 1998 (8) . In the following year its use was also approved in Europe, and then expanded to approximately 50 countries.
The implementation of the program in Brazil took place in 2013, after the publication of Portaria 522, of the Ministry of Health (MH) (1) . The scientific literature on this subject is still scarce, starting from the end of the 1990s. The main existing evidences The legislation with the protocol for the use of palivizumab in Brazil, approved by Portaria MH 522 in May 13, 2013, is followed for inclusion in the program in the State of São Paulo (1) .
One of the following criteria must be satisfied for the inclusion of children in the program: premature babies, born with a gestational age of 28 weeks or less and up to one year old or children up to 2 years old with chronic lung disease and/or congenital heart disease with hemodynamic repercussion (1) . Also, the use of the immunoglobulin must start one month before the seasonal period, and be repeated monthly (1) , including during hospitalization. The outcome variable was: hospitalization in the ICU for respiratory illness or symptoms (yes, no), considering the group that followed the protocol and the group that did not. The protocol was considered not followed when there was failure to take one or more doses of the regimen, as recommended by the Ministry of Health (1) .
The exposed group consisted of children who failed to receive at least one of the recommended doses of the immunoglobulin, and the non-exposed group consisted of children who received all doses of the immunoglobulin. 
Results
Among the 693 children in the cohort sample, 126 (18.2%) were hospitalized for respiratory disease or symptom during the study and 16 (2.7%) failed to receive a dose of the immunoglobulin. Specifically, among the 677 children who took all doses, 123 were hospitalized (18.2%), and among the 16 who failed to receive at least one dose, 3 (18.8%) were hospitalized, with no significant difference between these two groups, p=0.952.
The characteristics of the mothers and children participating in the study, as well as their living condition, are shown in Table 1 . In the bivariate analysis, the variables that were most associated with hospitalization for respiratory illness or symptoms were: application in CRIE; white mother, with 11 or more years of schooling and working as homemaker; family income per capita; number of people sleeping with the child and child with a history of surgical pathology or respiratory clinical pathology (Table 2) ; therefore, those variables were included in the final model regarding the failure of an application (Table 3) and in the final model that considered the amount of failures in the application of the immunoglobulin palivizumab (Table 4 ).
In Table 3 , it is possible to observe that the chance of hospitalization in ICU for respiratory illness or symptoms did not differ when comparing children who failed to take one dose to children who took all doses (p=0.913). 
Discussion
This study aimed to identify the impact of failures in the application of immunoglobulin palivizumab on ICU hospitalizations due to respiratory illness or symptom. Failure to receive immunoglobulin at least once during the seasonal period of RSV did not result in an increase in hospitalization.
The main finding, however, was the relevance of the number of doses missed, since at each occurrence, the risk of hospitalization increased by an average of 29%.
A favorable result was also found in a metaanalysis conducted in 2009, which showed a decrease in hospitalization and ICU admission among children who received the immunoglobulin palivizumab when compared to children who received placebo: p=0.0007, relative risk=0.29 and CI 95%=0.14-0.59 (9) . The effectiveness of this immunoglobulin was pointed out in other investigations, such as a cohort study carried out in Spain, which identified a hospitalization rate of 13.2%
among non-immunized children and of 3.9% among immunized children (10) . Also, a population-based study conducted in two Canadian cities found a reduction in the chance of hospitalization after the implementation of palivizumab (7.3% versus 3.0%) (11) .
In Brazil, a prospective cohort study with 198 children verified that 48 (24.2%) were hospitalized, 30 (15.2%) due to non-respiratory causes and 18 (9.1%) due to respiratory causes. In only one case (0.5%) the RSV (12) was identified, a value lower than the one found in another study(1.5%) (13) .
In the present study, the rate of hospitalizations in ICU for respiratory disease or symptom among children receiving all doses was 18.2%, almost twice the value found in the above-mentioned Brazilian cohort (12) . This value was also higher than the ones found in two American studies: The IMpact .
The explanation for these differences may be the absence of the etiological diagnosis of RSV during the hospitalization of the children. A positive aspect to highlight in this study was the carefulness to avoid memory bias: the questions about hospitalization were asked monthly and only those cases that required hospitalization in the ICU were considered, which, by its severity, would probably not be forgotten by the mother or caregiver in that short space of time.
Another difference can be highlighted: in the IMpact study (8) , the hospitalization rate among children who did not receive all the recommended doses (10.6%) was 55% higher than that observed among the children who received all doses (4,8%). In the present study, the comparison between no failure and one failure resulted in similar rates, respectively 18.2% and 18.8%. A hypothesis that may explain this fact is the proportion of children who failed to receive the immunoglobulin in this study (2.3%), a number significantly lower than that obtained in the IMpact study (7.0%).
The favorable situation of the children who received the immunoglobulin was evident, because, with each dose lost, the chance of hospitalization increased by 29%. Therefore, health services should conduct an active search for the children not receiving the doses according to the immunoglobulin palivizumab protocol (1) and adopt actions to strengthen the link between health professionals and families, increasing adherence to measures of protection and promotion of child health (15) .
A prospective cohort study conducted with .
Regarding more comprehensive studies, a metaanalysis addressing the hospitalization of children aged 2 years or less with bronchopulmonary dysplasia (15) , which included prospective and retrospective clinical trials, controlled or not, verified that the weighted mean of hospitalizations among non-treated children was 18.4%, while among children treated with the palivizumab it was 5.6%. It should be noted that these values refer to different samples for the cases treated or not, and that the studies were carried out in different countries (17) .
The non-isolation of the respiratory syncytial virus 
Conclusion
The use of the immunoglobulin palivizumab among eligible children, as recommended by Brazilian public policies, is important, due to the progressively greater risk of hospitalization in ICU for respiratory illness or symptoms at each dose missed.
The history of clinical respiratory pathology among children at risk of presenting RSV infection is a factor independently associated with hospitalization in ICU for respiratory illness or symptoms, and therefore, these children need to be carefully monitored.
In general, the importance of not missing immunoglobulin applications was demonstrated.
Actions in this direction may include guidance to health professionals to discuss with families the importance of appropriate and frequent applications, implementation of mechanisms for active search of absent patients, and scheduling the applications according to the recommendation.
